Drugs News and Research

RSS

Sanofi-aventis signs agreement to acquire TargeGen

TargeGen, Inc., a privately held biotechnology company focused on the development of small molecule kinase inhibitors today announced that the Company has agreed to be acquired by sanofi-aventis. Under the agreement, the ultimate purchase price will depend on the achievement of certain future milestones events and will total $560M if such milestones are fully realized. The closing of the transaction is expected to occur in the 3rd quarter of 2010.

1 Jul 2010

pSivida's licensee submits NDA to FDA for Iluvien

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a New Drug Application to the U.S. Food and Drug Administration for Iluvien for Diabetic Macular Edema.

1 Jul 2010

Study: Medicare 'pay-for-performance' could increase care inequality

"The U.S. government's plan to base Medicare payments to hospitals on certain quality-of-care measures could end up transferring funds away from hospitals in the nation's poorest, underserved areas," according to a study published Tuesday in the journal PLoS Medicine.

1 Jul 2010

Studies link anti-cholesterol statin drugs to increased risk of anxiety and depression

Scientists are reporting a possible explanation for the symptoms of anxiety and depression that occur in some patients taking the popular statin family of anti-cholesterol drugs, and reported by some individuals on low-cholesterol diets. These symptoms could result from long-term, low levels of cholesterol in the brain, the report suggests. It appears in ACS' weekly journal Biochemistry.

1 Jul 2010

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Fero Industries, Inc. is pleased to announce that it has closed the acquisition of certain intellectual property and other associated rights related to the production, marketing, and distribution of Sucanon, a treatment for Type II diabetes.

1 Jul 2010

Bortezomib may offer hope for treating inflammatory diseases: New research

Those looking for a new treatment for a range of inflammatory diseases like arthritis, multiple sclerosis, inflammatory bowel disease, and lupus may need to look no further than a drug already available for treating cancer. In a research report published in the July 2010 print issue of the Journal of Leukocyte Biology, Japanese scientists use mice to show that bortezomib, currently used to treat cancers that affect white blood cells, induces cell death only in harmful (active and proliferating) T cells, leaving the rest unharmed.

1 Jul 2010

Antibacterial ingredient in honey identified

Sweet news for those looking for new antibiotics: A new research published in the July 2010 print edition of the FASEB Journal explains for the first time how honey kills bacteria. Specifically, the research shows that bees make a protein that they add to the honey, called defensin-1, which could one day be used to treat burns and skin infections and to develop new drugs that could combat antibiotic-resistant infections.

30 Jun 2010

Investment report on BioCryst Pharmaceuticals

MicroStockProfit.com announces an investment report featuring BioCryst Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

30 Jun 2010

Call for incorporation of scientific evidence into illicit drug policies

Three leading scientific and health policy organizations today launched a global drive for signatories to the Vienna Declaration, a statement seeking to improve community health and safety by calling for the incorporation of scientific evidence into illicit drug policies. Among those supporting the declaration and urging others to sign is 2008 Nobel Laureate and International AIDS Society (IAS) Governing Council member Prof. Fran-oise Barr--Sinoussi, co-discoverer of HIV.

30 Jun 2010

Genetic variation makes women sub-fertile, less likely to respond to ovarian stimulating hormones

Researchers have discovered that some women carry a genetic variation that makes them sub-fertile and less likely to respond to ovarian stimulating hormones during fertility treatment. The discovery opens the way to identifying these women and devising personalised fertility treatments that could bypass the problem caused by the genetic abnormality.

30 Jun 2010

NORD urges FDA to reduce regulatory uncertainty in developing medicines for rare disorders

Noting that only about 200 of the nearly 7,000 diseases classified as rare currently have treatments, the National Organization for Rare Disorders (NORD) today called for a Food and Drug Administration (FDA) statement of policy on regulation of therapies for rare disorders.

30 Jun 2010

Medivir's rights issue changes number of shares and votes

The number of shares and the number of votes in Medivir have changed as a result of the rights issue carried out by the company as well as the exercise of employee stock options.

30 Jun 2010

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

New long term data showed that Vimpat- (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy. In addition post-hoc exploratory analyses showed that adjunctive lacosamide treatment reduced partial-onset seizure frequency and improved responder rates when added to a broad range of antiepileptic drugs (AEDs) including both traditional sodium channel-blocking agents and those that act on non-sodium channel-targets.

30 Jun 2010

Experts evlauate impact of Medicare Part D program on independent and chain pharmacies

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Medicare Part D) added prescription drug coverage to Medicare beginning in January 2006.

30 Jun 2010

2 new studies add to evidence of risks with diabetes drug Avandia as FDA prepares to debate it's safety

The Washington Post: Two new studies provide evidence "that the diabetes drug Avandia increases the risk of heart problems and strokes, renewing questions about the safety of the medication. ... The new research, released Monday, should prompt the Food and Drug Administration to remove the drug from the market, according to the researchers who led the analyses and several drug-safety advocates.

30 Jun 2010

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.

30 Jun 2010

Drugs News and Research

Sanofi-aventis signs agreement to acquire TargeGen

pSivida's licensee submits NDA to FDA for Iluvien

Study: Medicare 'pay-for-performance' could increase care inequality

Studies link anti-cholesterol statin drugs to increased risk of anxiety and depression

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Bortezomib may offer hope for treating inflammatory diseases: New research

Antibacterial ingredient in honey identified

Investment report on BioCryst Pharmaceuticals

Call for incorporation of scientific evidence into illicit drug policies

Genetic variation makes women sub-fertile, less likely to respond to ovarian stimulating hormones

NORD urges FDA to reduce regulatory uncertainty in developing medicines for rare disorders

Medivir's rights issue changes number of shares and votes

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

Experts evlauate impact of Medicare Part D program on independent and chain pharmacies

2 new studies add to evidence of risks with diabetes drug Avandia as FDA prepares to debate it's safety

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

New hope for patients with drug-resistant depression

Asbestos induces cell necrosis, promotes tumor growth

FDA grants approval for first generic version of Effexor XR antidepressant capsules

Recent, upcoming FDA efforts address rare, 'neglected' diseases

Drug Discovery - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News